All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Relief Therapeutics
Deal Size: $2.4 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 20, 2021
Details:
Relief will gain further pending intellectual property rights that may cover RLF-100TM inhaled formulation specifications and the potential application of inhaled Aviptadil in the treatment of Acute Respiratory Distress Syndrome and Checkpoint Inhibitor-induced Pneumonitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
Details:
Half-century-old aviptadil, studied over the years for a variety of uses including erectile dysfunction and pulmonary fibrosis, was part of Relief's portfolio when the COVID-19 pandemic began, prompting the company to test it against the new coronavirus.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Relief Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
NeuroRx and Relief Therapeutics have met the 165 patient enrollment target agreed with the U.S. Food and Drug Administration (FDA) in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating Respiratory Failure in patients with Critical COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sulforaphane
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: SFX-01
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
This Phase II/III trial will investigate whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with community-acquired pneumonia who have been or are being tested for suspected COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: NeuroRx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Relief, NeuroRx have met the 165 patient enrollment target agreed with the U.S. Food and Drug Administration (FDA) in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating Respiratory Failure in patients with Critical COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MultiStem Cell Therapy
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: HLCM051
Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
The Company has conducted extensive research exploring MultiStem cell therapy for the treatment of pulmonary distress and recently completed an exploratory Phase 1/2 clinical trial for the treatment of ARDS (the MUST-ARDS study).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Opaganib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Yeliva
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: State of Pennsylvania
Deal Size: $0.3 million Upfront Cash: Undisclosed
Deal Type: Funding September 03, 2020
Details:
A global Phase 2/3 study in up to 270 patients hospitalized with severe COVID-19 pneumonia, and a U.S. Phase 2 study in up to 40 patients, are ongoing with opaganib, a novel sphingosine kinase-2 selective inhibitor with dual anti-inflammatory and anti-viral properties.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nitric Oxide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: iNOPulse
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
The results from this first cohort established the safety of the iNO30 dose and confirmed the potential for INOpulse to provide clinically meaningful benefits in levels of daily activity in this patient population.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sarconeos
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO101
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Biophytis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 08, 2020
Details:
French biotech firm Biophytis will assess its Sarconeos (BIO101) drug as a treatment for respiratory failure caused by Covid-19 after partnering with contract research organisation (CRO) SGS.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
